<i>RYK</i> Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

<i>RYK</i> Gene Expression Associated with Drug Response Variation of Temozolomide and Clinical Outcomes in Glioma Patients

Temozolomide (TMZ) chemotherapy is an important tool in the treatment of glioma brain tumors. However, variable patient response and chemo-resistance remain exceptionally challenging. Our previous genome-wide association study (GWAS) identified a suggestively significant association of SNP rs4470517...

Full description

Bibliographic Details
Main Authors: Ricardo D. Gonzalez, George W. Small, Adrian J. Green, Farida S. Akhtari, Tammy M. Havener, Julia C. F. Quintanilha, Amber B. Cipriani, David M. Reif, Howard L. McLeod, Alison A. Motsinger-Reif, Tim Wiltshire
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Pharmaceuticals
Subjects:
GWAS
chemotherapy
sensitivity
resistance
glioma
drug response
Online Access:https://www.mdpi.com/1424-8247/16/5/726

Internet

https://www.mdpi.com/1424-8247/16/5/726

Similar Items